27 results about "Low Grade Malignant Neoplasm" patented technology

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

This invention discloses a methylation marker for the differential diagnosis of malignant and benign breast tumors. The invention provides the application of the methylated SH3PXD2B gene as a marker in product preparation; the product is used for at least one of the following purposes: (1) distinguishing between benign and malignant breast tumors; (2) distinguishing between benign breast tumors and different subtypes or stages of malignant breast tumors; (3) distinguishing between different subtypes or stages of malignant breast tumors. This invention has significant scientific and clinical application value for differentiating between benign and malignant breast tumors, different subtypes or stages of malignant breast tumors, and guiding the development of reasonable clinical treatment plans.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

This invention discloses an asymmetric magnetic nanoparticle, its preparation method, and its applications. The asymmetric magnetic nanoparticle comprises, from the inside out, an Er-doped NaYF4 core, a NaYF4 layer, and an asymmetric mesoporous silica layer, with Fe2C nanoparticles loaded on the asymmetric mesoporous silica layer. The asymmetric magnetic nanoparticle of this invention possesses advantages such as enabling remote and precise navigation, efficient and stable enrichment in target areas, and long-term high-contrast afterglow emission. It can not only improve the safety and effectiveness of malignant tumor treatment but also achieve integrated and visualized diagnosis and treatment processes, making it suitable for large-scale industrial applications.

This invention relates to a cyclic polypeptide molecular probe targeting neurocilia protein-1 (NRP-1), its preparation method, and its applications. The cyclic polypeptide molecular probe comprises the structure shown in Formula I or Formula II, where R1 is the structure shown in Formula III or Formula IV; and R2 is a radiolabeled nuclide or a radiolabeled nuclide including a bifunctional chelating group. The technical solution of this invention exhibits excellent targeting specificity and high sensitivity for NRP-1 protein, enabling visualization of NRP-1-highly expressing tumors (such as fibrosarcoma, lung cancer, pancreatic cancer, or breast cancer) and NRP-1-positive lesions (such as metabolic diseases, sclerotic lesions, or autoimmune diseases) on positron emission tomography (PET). It shows great promise in the early diagnosis of NRP-1-highly expressing malignant tumors and in guiding clinical NRP-1 monoclonal antibody treatment regimens.

The present application relates to a kind of PROTAC compound targeted degradation CDK2 and its preparation method and application, provide a kind of PROTAC compound, can targeted degradation CDK2, compared with existing CDK2 inhibitor, the small molecule compound prepared by the present application can effectively induce the degradation of CDK2 protein in MCF-7 cell, with good inhibiting MCF-7 cell proliferation ability, show better treatment effect to breast cancer, have potential to become effective treatment mode for treating malignant tumor.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The present application relates to the use of [10]-shogaol in the preparation of a medicament for preventing and / or treating tumors sensitive to ferroptosis. Specifically, the present application provides a method for screening ferroptosis inducers, comprising the following steps: taking cells sensitive to ferroptosis, applying a candidate compound to a test group, applying [10]-shogaol to a positive control group, applying [6]-shogaol to a non-ferroptosis inducer group, and not applying any compound to a blank control group; detecting the lipid peroxidation level in the cells of each group; comparing the lipid peroxidation levels of the test group and the other groups to detect whether the candidate compound is a ferroptosis inducer. The [10]-shogaol can effectively induce ferroptosis in various malignant tumor cells such as breast cancer, colorectal cancer, melanoma, etc., and the mechanism of action depends on the accumulation of lipid peroxidation, and this effect can be specifically blocked by ferroptosis inhibitors.

The present invention relates to a PROTAC compound for targeted degradation of CDK2, a preparation method therefor and a use thereof, and provides a PROTAC compound that is capable of targeted degradation of CDK2. Compared with existing CDK2 inhibitors, the small-molecule compound prepared by the present invention can effectively induce the degradation of CDK2 protein in MCF-7 cells, exhibits good ability to inhibit the proliferation of MCF-7 cells, demonstrates favorable therapeutic effects against breast cancer, and has the potential to become an effective treatment modality for malignant tumors.

This invention relates to the field of pharmaceutical technology, specifically disclosing a method for preparing and applying acid-sensitive environment-responsive PEGylated self-assembled micelles. The key technical points are as follows: the micelles are formed by the self-assembly of a 0831A-Hyd-mPEG conjugate in an aqueous solution. This conjugate is prepared through the following steps: first, monomethoxy polyethylene glycol (mPEG) is reacted with p-aldehyde benzoic acid to generate mPEG-CHO, which is then linked to 0831A (SKLB060-methionine) via an acylhydrazone bond; wherein the number-average molecular weight of mPEG is 2000; the average particle size of the micelles is approximately 157 nm, exhibiting significant pH-responsive drug release characteristics, with a cumulative drug release rate of 69.46±2.13% after 48 hours at pH 5.0, compared to only 22.94±0.67% at pH 7.4. The micelle structure of the present invention is well-defined and easy to prepare. It can effectively prolong the in vivo circulation time of the drug and significantly reduce its systemic toxicity while retaining the antitumor activity of 0831A. It is particularly suitable for preparing drugs for treating malignant tumors such as colorectal cancer.

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The application discloses an in-vivo drug delivery device, and relates to the technical field of medical intervention instruments.The main body of the in-vivo drug delivery device is made of PEG powder and 50:50 proportion of PLGA medical degradable high-molecular material, is formed through a salt pore forming process, and is internally provided with uniform and slow-release pores.The size can be adapted to different target blood vessels, the device is implanted into a lesion blood-supplying blood vessel through an intervention mode, and the drug loading formula can be flexibly adjusted according to diseases, and heparin and dexamethasone are added to prevent thrombosis and suppress inflammation.The in-vivo drug delivery device can realize 1-3 month controllable slow release of drugs, accurately delivers the drugs to a lesion at a high concentration, solves the problems of poor curative effect and large toxic and side effects of systemic drug delivery, is suitable for local treatment of malignant tumors and refractory chronic inflammation, and finally is completely degraded without residue, and does not need secondary operation.The in-vivo drug delivery device has the advantages of simple structure, flexible drug loading, good biocompatibility, wide clinical application range, and effectively makes up for the technical defects of existing local drug delivery devices.

Provided are a pharmaceutical combination and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and use thereof in the preparation of a medicine for treating a malignant tumor disease. The other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as palbociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the above.

The application discloses a PROTAC compound with a structure of formula I and application of the PROTAC compound in preparation of a pharmaceutical preparation for preventing or treating diseases caused by mediation of a T cell receptor signal path related protein (including HPK1, LCK, GLK, PCKθ and ITK proteins), such as a malignant tumor.

The present application relates to the field of biological medicine, and particularly relates to a kind of targeting CD19 nanobody and its preparation method and application.The present application provides a kind of nanobody targeting CD19, nucleic acid substance encoding the above-mentioned single domain antibody, corresponding expression vector and the host cell capable of expressing the nanobody targeting CD19.The nanobody provided by the present application has excellent specific CD19 binding capacity, and the nanobody affinity can reach 3.855x10 ‑9 ‌, show that the nanobody provided by the present application has highly specific binding activity, and has important application value in the treatment of B cell malignant tumor.

Disclosed herein are methods for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphoblastic leukemia (ALL)), using an anti-Galectin-9 antibody (e.g., G9.2-17(IgG4). In some embodiments, the anti-Galectin-9 antibody is used as a monotherapy.

The present invention relates to the field of biotechnology, medicine, in particular, oncology and pharmaceuticals, and is directed to ready-to-use dosage forms of a medicinal product for combination gene-directed enzyme prodrug therapy—immune therapy of human solid malignant neoplasms.Two variants of two-component dosage forms of the medicinal product are proposed. In the first variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a frozen aqueous solution, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection, intended for administration to a patient, is prepared ex tempore by thawing the referenced two components and mixing them.In the second variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a lyophilisate, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection intended for administration to a patient is prepared ex tempore by reconstituting the first component by adding water, thawing the second component and mixing them.The proposed dosage forms can be used for the treatment of human solid malignant neoplasms. The two proposed dosage forms demonstrate high stability and retain their therapeutic efficacy for at least 18 months.

The present invention relates to a pharmaceutical composition useful for preventing or treating malignant tumors and, to a composition for preventing or treating malignant neoplasm, comprising, as an active ingredient, at least one selected from the group consisting of a compound represented by chemical formula (1), a pharmaceutically acceptable salt, a hydrate, a solvate, and a prodrug of the compound, and a combination thereof.

This application relates to the preparation and application of a gambogeylic acid formulation targeting malignant tumors. It employs a three-layer structure: the core is a gambogeylic acid-black phosphorus quantum dot complex, possessing both chemotherapy and photothermal therapy functions; the middle layer consists of cryogenically frozen NK92 MI cell-derived nanovesicles, providing natural immune targeting and killing capabilities; the outer shell is a hyaluronic acid chelate, enabling active targeting and pH / photothermal responsive drug release. The core of its preparation method lies in using coaxial electrospray technology to form the three layers in one step, resulting in a highly efficient process and good formulation stability. This formulation can achieve synergistic photothermal-chemo-immunotherapy and simultaneously possesses near-infrared fluorescence and photoacoustic multimodal imaging capabilities, effectively solving the problems of poor targeting, significant toxic side effects, and lack of real-time monitoring associated with traditional chemotherapy. It demonstrates significant advantages and application potential in the precision treatment and diagnosis of solid tumors.

The application discloses YY20394 and ABT199 combination in the application of preparing a drug for treating acute myeloid leukemia. The application firstly finds that YY20394 and ABT199 have a synergistic effect on the treatment of acute myeloid leukemia, and the treatment effect of acute myeloid leukemia with MCL-1 overexpression can be significantly improved by combining YY20394 and ABT199. The application provides a brand-new treatment scheme for the technical field of blood system malignant tumor treatment, and has important scientific significance and clinical application value.

[0003] Embodiments of the present disclosure provide methods and compositions for treating hematopoietic malignancies (e.g., acute myeloid leukemia). In some embodiments, the present disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.

The application is a malignant tumor treatment dose optimization method and system based on multi-domain digital twinning. The system integrates patient multi-dimensional data in real time, constructs at least two digital twins respectively, sets a multi-domain coupled joint loss function on this basis, and automatically optimizes the future dosing curve using differentiable neural architecture search. A local weighted meta-learning strategy is introduced to quickly fine-tune the twin parameters under small samples, ensuring that the next cycle dose recommendation is quickly given. The clinical guidelines and safety rules are coded into a differentiable constraint layer and embedded in the network forward propagation to ensure that the dose recommendation is automatically compliant. All decision-making processes and data are time-stamped and stored by blockchain to form an unalterable diagnosis and treatment evidence chain. The application realizes the leap from static prediction to dynamic optimization and from single-point decision to closed-loop feedback, providing an intelligent, interpretable and traceable decision support system for precise treatment of malignant tumors.